Immuneering Advances Atebimetinib in Pancreatic Cancer
NEW YORK – August 26, 2026 Immuneering Corporation (Nasdaq: IMRX) highlighted its continued focus on first-line metastatic pancreatic cancer...
MEK inhibitor
Advertisement
NRG Therapeutics Expands Leadership to Accelerate Drug Pipeline
Stevenage, United Kingdom, December 1, 2025 NRG Therapeutics has announced the appointment of Dr. Paul Thompson as Chief Development...
Pasithea Raises $60M to Advance MEK Program and R&D Pipeline
Miami, Florida, November 28, 2025 Pasithea Therapeutics has announced the pricing of a $60 million public offering ,strengthening its...
Koselugo Secures US Approval, Advancing Targeted NF1 Care
Wilmington, Delaware, November 2025 AstraZeneca has announced that Koselugo (selumetinib) has received expanded FDA approval in the United States...
Pasithea Activates UAB Clinical Site for PAS-004 NF1 Trial
MIAMI, November 4, 2025: Pasithea Therapeutics Corp. has announced the activation of a new clinical trial site at the...
Advertisement
